Rocket Pharmaceuticals/$RCKT
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Rocket Pharmaceuticals
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
- Ticker
- $RCKT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 202
- Headquarters
- Cranbury, United States
- Website
- www.rocketpharma.com
RCKT Metrics
BasicAdvanced
$267M
-
-$0.15
0.47
-
Price and volume
Market cap
$267M
Beta
0.47
52-week high
$5.45
52-week low
$2.17
Average daily volume
2.1M
Financial strength
Current ratio
9.245
Quick ratio
9.06
Long term debt to equity
0.059
Total debt to equity
0.067
Interest coverage (TTM)
-101.42%
Profitability
EBITDA (TTM)
-182.177
Effective tax rate (TTM)
-99.91%
Management effectiveness
Return on assets (TTM)
-28.42%
Return on equity (TTM)
-4.77%
Valuation
Price to book
0.72
Price to tangible book (TTM)
0.88
Price to free cash flow (TTM)
35.01
Free cash flow yield (TTM)
2.86%
Free cash flow per share (TTM)
0.07
Growth
Earnings per share change (TTM)
-93.83%
3-year earnings per share growth (CAGR)
-63.95%
What the Analysts think about RCKT
Analyst ratings (Buy, Hold, Sell) for Rocket Pharmaceuticals stock.
Analyst projections of the future price of Rocket Pharmaceuticals stock.
RCKT Financial Performance
Revenues and expenses
RCKT Earnings Performance
Company profitability
Upcoming events
No upcoming events
RCKT News
AllArticlesVideos
Rocket Pharmaceuticals shares rise 4% after securing access to $150 million credit facility
Proactive Investors4 weeks ago
Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar
Business Wire4 weeks ago
Rocket Pharmaceuticals Details RP-A501 Pivotal Plan After Safety Reset
MarketBeat1 month ago
Funds containing RCKT
Fund name | Fund size | $RCKT weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.02% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.02% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.01% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.